Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
- Conditions
- Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
- Trial name
- NCT04786262
- Testing
- VX-880, VX-017
- Where
- 29 sites in United States, Canada and 8 more
- Volunteers
- 57 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetes Mellitus
Single Ascending Dose Trial in Patients With Type 2 Diabetes
The purpose of this study is to determine whether AMG 876 is safe and well tolerated in subjects with type 2 diabetes.
- Trial name
- NCT01492465
- Testing
- AMG 876
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects
Albiglutide (Alb) is a novel analogue of glucagon-like peptide-1 (GLP-1) has been developed and approved for the treatment of type 2 diabetes mellitus.
- Trial name
- NCT02660736
- Testing
- Albiglutide Liquid Auto-injector, Albiglutide Lyophilized DCC Pen Injector
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Impaired Fasting Glucose
Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose
The Purpose of this study is to compare the effects of 2 types of dietary fiber, psyllium and microcrystalline cellulose (MCC), on glycemic measures in subjects with impaired fasting glucose.
- Trial name
- NCT01549600
- Testing
- psyllium, Microcrystalline Cellulose
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Hypertension, Diabetes
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and…
- Conditions
- Hypertension, Diabetes, Proteinuria
- Trial name
- TANDEM (NCT00234871)
- Testing
- trandolapril/verapamil, Lotrel (amlodipine/benazepril)
- Volunteers
- 357 people
- Sponsor
- Abbott
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Diabetes Mellitus, Type 2
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
This is a stepped glucose clamp study designed to investigate the effect of treatment with albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus.
- Trial name
- NCT01475734
- Testing
- albiglutide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Patients
A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin
This is a randomized, double-blind, placebo-controlled, repeat-dose study to evaluate the safety, tolerability, PK, and PD of L47 as an add-on treatment to stable metformin therapy in patients with T2DM.
- Trial name
- NCT04662164
- Testing
- hepalatide
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes
This trial is conducted in Africa. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart plus OAD compared to biphasic insulin aspart alone on blood glucose control in type 2 diabetes.
- Trial name
- NCT00624364
- Testing
- biphasic insulin aspart, metformin
- Where
- 15 sites in South Africa
- Volunteers
- 140 people
- Sponsor
- Novo Nordisk A/S
Diabetic Peripheral Neuropathy
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
- Trial name
- DPN (NCT03219320)
- Testing
- NYX-2925
- Where
- 35 sites in United States
- Volunteers
- 301 people
- Sponsor
- Aptinyx
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking…
- Trial name
- NCT00528372
- Testing
- Dapagliflozin, Metformin
- Where
- 78 sites in United States, Canada and 2 more
- Volunteers
- 1,067 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
In this integrated, Phase I study, the safety, tolerability, food effect, and pharmacokinetic (PK) properties of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR…
- Trial name
- NCT03138356
- Testing
- 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet, 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet, 5 mg dapagliflozin / 850 mg metformin XR FDC
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Xerosis Cutis
Comparison Dry Foot Skin Between Diabetic and Non-diabetic Subjects and the Effects of Two Cosmetic Foot Care Products
The overall aims of this study are to compare the structure and function of dry to very dry and cracked foot skin between diabetic and nondiabetic subjects and to evaluate the effects of two cosmetic leave-on products on dry and…
- Trial name
- NCT05046015
- Testing
- 10% Urea foot lotion, 10% Urea foot ointment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Galderma R&D
Spinal Cord Injuries, Type 2 Diabetes
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition.
- Trial name
- NCT06706284
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Marzieh Salehi
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety Study of BMS-823778 in Subjects With Type 2 Diabetes
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on fasting plasma glucose (FPG).
- Trial name
- NCT01111955
- Testing
- BMS-823778, Metformin
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
This study is conducted in Asia. The aim of this observational study is to evaluate the quality of life and clinical outcomes in subjects using NovoMix® 30 (biphasic insulin aspart 30) for the treatment of diabetes mellitus under…
- Trial name
- IMPROVE Life (NCT00696163)
- Testing
- biphasic insulin aspart 30
- Where
- India
- Volunteers
- 24,975 people
- Sponsor
- Novo Nordisk A/S
T2DM
A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes
This is a randomized, double-blind, placebo-controlled, single-dose escalation trial was designed. There are 6 dose groups and 1 optional dose group: 0.5 mg, 2 mg, 8 mg, 25mg, 50 mg, 100 mg and 150 mg (optional).
- Trial name
- NCT05996380
- Testing
- SHR-3167
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.